Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (Weighted Average) (2020 - 2025)

Rani Therapeutics Holdings has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $131.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $131.6 million for Q4 2025, up 172255.59% from a year ago — trailing twelve months through Dec 2025 was $131.6 million (up 172255.59% YoY), and the annual figure for FY2025 was $131.6 million, up 172255.59%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $131.6 million at Rani Therapeutics Holdings, up from $76.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for RANI hit a ceiling of $131.6 million in Q4 2025 and a floor of $19534.0 in Q4 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $25.4 million (2023), compared with a mean of $30.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 58.55% in 2021 and later surged 172255.59% in 2025.
  • Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) stood at $19534.0 in 2021, then increased by 21.93% to $23817.0 in 2022, then increased by 7.09% to $25505.0 in 2023, then surged by 199.3% to $76336.0 in 2024, then surged by 172255.59% to $131.6 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $131.6 million (Q4 2025), $76.3 million (Q3 2025), and $35.0 million (Q2 2025) per Business Quant data.